A unique collaboration between Boehringer Ingelheim Canada and the University Hospital Foundation is helping health providers gain a better understanding of oxygen needs for interstitial lung diseases (ILD) patients in Alberta, while improving access in the process.
The Boehringer Ingelheim Interstitial Lung Disease Oxygen Access (ABILD02) partnership is pan- provincial in scope and aims to better understand the patient population living with ILD that requires oxygen therapy and identify facilitators and barriers to oxygen therapy use for the management of ILD through stakeholder consultations. A third goal of the initiative is to examine the impact of oxygen therapy for people living with ILD and exertional hypoxemia, a condition where oxygen levels in the blood drop during movement, causing shortness of breath and in severe cases, interference with heart and brain function. 1
This collaboration is an example of how strategic public-private partnerships can accelerate health innovation and create sustainable solutions that help improve the healthcare system. Learn more about our partnership.
----
1Cleveland Clinic Hypoxemia